There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Angie Drakulich was editorial director of Pharmaceutical Technology.

Articles

The World Health Organization released new guidelines this week for the treatment of malaria and the first-ever guidelines on procuring safe and efficacious antimalarial drugs.

WHO Releases New Malaria Treatment and Drug-Procurement Guidelines

Exelixis And XenoPort Announce Job Cuts; GSK Dedicates India Facility; And More.

Week Of March 8, 2010: Company And People Notes: Exelixis And XenoPort Announce Job Cuts; GSK Dedicates India Facility; And More.

The US Food and Drug Administration recently published guidance for the characterization and qualification of cell substrates, viral seeds, and other biological materials used to manufacture viral vaccines for human use.

FDA Issues Guidance for Manufacturing Cell-Based Viral Vaccines

Astellas Pharma Makes Bid for OSI Pharmaceuticals; Ringo Retiring From Pfizer; And More.

Week Of March 1, 2010: Company And People Notes: Astellas Pharma Makes Bid for OSI Pharmaceuticals; Ringo Retiring From Pfizer; And More.

Editors' Picks of Pharmaceutical Science & Technology Innovations

In the Spotlight March 2010

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Report from India

Industry Pipeline

Current methods for establishing visible residue limits (VRLs) are not statistically justifiable. The author proposes a method for estimating VRLs based on logistic regression.

Statistically Justifiable Visible Residue Limits

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes